H.C. Wainwright raised the firm’s price target on AxoGen (AXGN) to $26 from $25 and keeps a Buy rating on the shares. The company reported a Q3 beat and upped its 2025 outlook, the analyst tells investors in a research note. The firm believes AxoGen’s execution of its market development strategy should drive revenue growth in the coming quarters.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN:
- AxoGen’s Strong Market Position and Growth Potential Justify Buy Rating
- AxoGen price target raised to $27 from $24 at Canaccord
- AxoGen price target raised to $34 from $26 at Citizens JMP
- Axogen Reports Strong Q3 2025 Results, Raises Guidance
- AxoGen’s Earnings Call Highlights Robust Growth and Strategic Progress